108
Participants
Start Date
August 19, 2020
Primary Completion Date
October 23, 2023
Study Completion Date
October 25, 2023
Apalutamide
Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) oral tablets during the main study and sub-study.
ADT
Participants will receive ADT intramuscular or subcutaneously during the main study.
Relugolix
Participants will receive 120 mg of relugolix following a loading dose of 360 mg of (3 tablets of 120 mg each) relugolix during the sub-study.
Associated Medical Professionals, Syracuse
Great Lakes Physician PC d/b/a Western New York Urology Associates, Cheektowaga
Lancaster Urology, Lancaster
MidLantic Urology, Bala-Cynwyd
Lexington Urology, West Columbia
Virginia Urology, Richmond
Urology Of Virginia, Pllc, Virginia Beach
Associated Urologists of North Carolina, Raleigh
Carolina Urologic Research Center, Myrtle Beach
Urological Research Network, Hialeah
Urology Associates, Nashville
The Urology Group, Cincinnati
First Urology, PSC, Jeffersonville
Michigan Institute of Urology, PC, Troy
The Iowa Clinic, West Des Moines
Wichita Urology Group, Wichita
Adult Pediatric Urology & Urogynecology, P.C, Omaha
Ochsner LSU Health Shreveport - Regional Urology, Shreveport
Arkansas Urology, Little Rock
Houston Metro Urology, Houston
Urology San Antonio Research, San Antonio
Urology Austin, Austin
The Urology Center of Colorado, Denver
Foothills Urology - Golden Off, Lakewood
Idaho Urologic Institute, Meridian
Arizona Urology Specialists, Tucson
Arizona Urology Specialists, Tucson
Genesis Research, Torrance
Skyline Urology, Sherman Oaks
Oregon Urology Institute, Springfield
Spokane Urology, Spokane
New Jersey Urology LLC, Voorhees Township
Janssen Research & Development, LLC
INDUSTRY